Πέμπτη 30 Μαρτίου 2017

Haematological cancer: Anti-PD-1 therapy with nivolumab after allo-HSCT for Hodgkin lymphoma.

Related Articles

Haematological cancer: Anti-PD-1 therapy with nivolumab after allo-HSCT for Hodgkin lymphoma.

Nat Rev Clin Oncol. 2017 Mar 29;:

Authors: Killock D

PMID: 28352133 [PubMed - as supplied by publisher]



http://ift.tt/2obil13

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου